Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) to expand its ModiFY.
CHIEF EXECUTIVE OFFICER S STATEMENT I am pleased to report the Group s interim results for the six-month period ended 31 October 2023. During the period, Scancell.
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF), a developer of immunotherapies for cancer and infectious diseases, has reached a pivotal milestone in its.